A consortium of investors led a $93m Series A round in Bonum Therapeutics.

A consortium of investors, including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, 3x5 Partners, Codon Capital and Vivo Capital led a $93m Series A round in Bonum Therapeutics, a biopharmaceutical company. “We have enormous confidence in the Bonum team’s ability to advance a broad portfolio of first-in-class therapeutics through the development process. With support from this strong syndicate of new and existing investors, Bonum is well positioned to deliver on the potential of its validated platform,” Samuel Bjork, Digitalis Ventures Partner.